Effect of benzydamine on exocytosis and respiratory burst in human neutrophils and mononuclear phagocytes
- 1 July 1985
- journal article
- research article
- Published by Springer Nature in Inflammation Research
- Vol. 16 (5) , 346-352
- https://doi.org/10.1007/bf01982871
Abstract
The effect of benzydamine on stimulus-dependent respiratory burst activity and enzyme release was tested in human neutrophils, monocytes and monocyte-derived macrophages. Establihsed anti-inflammatory compounds, indomethacin, phenylbutazone and bufexamac, were tested for comparison. Care was taken to avoid cytotoxic or cytolytic concentrations of the test compounds, and their effect on release of lactate dehydrogenase was also tested. Release of specific and azurophil granules contents were induced in human neutrophils by A23187, PMA and fMLP with and without cytochalasin B pretreatment. Benzydamine inhibited stimulus-dependent release of vitamin B12-binding proteins, a marker for the specific granules, in a concentration-dependent fashion. By contrast, phenylbutazone and bufexamac were practically inactive. The effect of benzydamine on exocytosis of azurophil granules was tested in cytochalasin B-pretreated neutrophils. Benzydamine, again in contrast to the two reference anti-inflammatory compounds, inhibited release concentration-dependently also under these conditions. The concentration of the compound which inhibited exocytosis by 50% was 30–100 μM in normal and 3–10 μM in cytochalasin B-treated neutrophils. The effect of benzydamine and reference compounds on the respiratory burst was tested by assaying for superoxide formation in neutrophils and H2O2 formation in mononuclear phagocytes. Benzydamine was inactive on neutrophils and inhibited slightly the burst response of monocytes and macrophages. Two reference compounds, bufexamac and phenylbutazone, were generally more active. The strongest inhibitory effect was that of phenylbutazone on fMLP-stimulated cells. Benzydamine lacked activity receptor of formylated chemotactic peptides. The profile of activity of benzydamine shown in these experiments on human phagocytes suggest that this compound may act therapeutically by decreasing the release of enzymes and other granule constitutents from stimulated neutrophils.Keywords
This publication has 15 references indexed in Scilit:
- Isolation of large numbers of highly purified lymphocytes and monocytes with a modified centrifugal elutriation techniqueJournal of Immunological Methods, 1981
- Receptor-directed inhibition of chemotactic factor-induced neutrophil hyperactivity by pyrazolon derivatives. Definition of a chemotactic peptide antagonist.Journal of Clinical Investigation, 1980
- On the Mode of Action and Biochemical Properties of Anti-Inflammatory DrugsBiochemical Society Transactions, 1979
- Subcellular localization of the superoxide-forming enzyme in human neutrophils.Journal of Clinical Investigation, 1979
- Oxygen-Dependent Microbial Killing by PhagocytesNew England Journal of Medicine, 1978
- BIOCHEMICAL AND MORPHOLOGICAL CHARACTERIZATION OF AZUROPHIL AND SPECIFIC GRANULES OF HUMAN NEUTROPHILIC POLYMORPHONUCLEAR LEUKOCYTESThe Journal of cell biology, 1974
- SECRETION OF PLASMINOGEN ACTIVATOR BY STIMULATED MACROPHAGESThe Journal of Experimental Medicine, 1974
- Quantitative determination of prostaglandins and malondialdehyde formed by the arachidonate oxygenase (prostaglandin synthetase) system of bovine seminal vesicleProstaglandins, 1973
- Researches on the topical activity of benzydamineEuropean Journal of Pharmacology, 1968
- Studies on the absorption and elimination of benzydamine in the mouse, rat, dog, and man.1966